Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 11/20 | 0.41 |
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093401 | 1.00 | PDK4 (0.47) | PDK4NAMPTHSD11B1GRM5GRM1 | |
| SCHEMBL6092726 | 0.94 | PDK4 (0.47) | PDK4NAMPTHSD11B1GRM5GRM1 | |
| SCHEMBL6094854 | 0.91 | HSD11B1 (0.42) | NAMPTHSD11B1CYP2D6AVPR1A | |
| SCHEMBL6094853 | 0.91 | HSD11B1 (0.42) | NAMPTHSD11B1CYP2D6AVPR1A | |
| SCHEMBL6093241 | 0.90 | PDK4 (0.47) | PDK4NAMPTHSD11B1GRM5GRM1 | |
| SCHEMBL6090129 | 0.89 | PDK4 (0.52) | PDK4NAMPTHSD11B1GRM5GRM1 | |
| SCHEMBL6092435 | 0.89 | HSD11B1 (0.44) | HSD11B1CYP2D6AVPR1A | |
| SCHEMBL6092918 | 0.85 | HSD11B1 (0.42) | NAMPTHSD11B1CYP2D6AVPR1A | |
| SCHEMBL13606705 | 0.82 | PDK2 (0.51) | NAMPTHSD11B1CYP2D6AVPR1A | |
| SCHEMBL6094326 | 0.81 | HSD11B1 (0.44) | HSD11B1CYP2D6AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122210-A1 | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same | INCYTE CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122210-A1 | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same | HSD11B1, HSD11B2, HSD17B1 | PDK4 578/4885NAMPT 1191/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.